Table 2.
Summary of immunohistochemical expression of arginase-1and HepPar-1 in all the studied cases
|
Arginase-1 |
HepPar-1 |
|||||||
|---|---|---|---|---|---|---|---|---|
|
Negative |
Positive |
Total positive |
Negative |
Positive |
Total positive |
|||
| 0 (%) | 1+(%) | 2+(%) | No (%) | 0(%) | 1+(%) | 2+(%) | No (%) | |
|
Hepatocellular carcinoma (HCC), (no=50): |
8 (16) |
19 (38) |
23 (46) |
42 (84) |
15 (30) |
16 (32) |
19 (38) |
35 (70) |
| well differentiated (no=11) |
0 (0) |
3 (27.3) |
8 (72.7) |
11 (100) |
0 (0) |
4 (36.4) |
7 (63.6) |
11 (100) |
| moderately differentiated (no=30) |
3 (10) |
12 (40) |
15 (50) |
27 (90) |
8 (26.7) |
10 (33.3) |
12 (40) |
22 (73.3) |
| poorly differentiated (no=9) |
5 (55.6) |
4 (44.4) |
0 (0) |
4 (44.4) |
7 (77.8) |
2 (22.2) |
0 (0) |
2 (22.2) |
|
Metastatic carcinoma (MC) (no=38) |
37 (97.4) |
1 (2.6) |
0 (0) |
1 (2.6) |
32 (84.2) |
2 (5.3) |
4 (10.5) |
6 (15.8) |
| Colonic (no=25) |
25 (100) |
(0) |
0 (0) |
0 (0) |
22 (88) |
1 (4) |
2 (8) |
3 (12) |
| Gastric (no=6) |
6 (100) |
0 (0) |
0 (0) |
0 (0) |
3 (50) |
1 (16.7) |
2 (33.3) |
3 (50) |
| Renal cell carcinoma (no=2) |
2 (100) |
0 (0) |
0 (0) |
0 (0) |
2 (100) |
0 (0) |
0 (0) |
0 (0) |
| Pancreas (no=2) |
1 (50) |
1 (50) |
0 (0) |
1 (50) |
2 (100) |
0 (0) |
0 (0) |
0 (0) |
| Lung (no=2) |
2 (100) |
0 (0) |
0 (0) |
0 (0) |
2 (100) |
0 (0) |
0 (0) |
0 (0) |
| Gall bladder (no=1) |
1 (100) |
0 (0) |
0 (0) |
0 (0) |
1 (100) |
0 (0) |
0 (0) |
0 (0) |
|
Cholangiocarcinoma (no=12) |
11 (91.7) |
1 (8.3) |
0 (0) |
1 (8.3) |
10 (83.3) |
1 (8.3) |
1 (8.3) |
2 (16.7) |
|
Non-neoplastic cirrhotic liver tissues adjacent to HCC(no=42) |
0 (0) |
0 (0) |
42 (100) |
42 (100) |
0 (0) |
0 (0) |
42 (100) |
42 (100) |
|
Non-neoplastic liver tissue adjacent to MC (no= 9) |
0 (0) |
0 (0) |
9 (100) |
9 (100) |
0 (0) |
0 (0) |
9 (100) |
9 (100) |
| Normal liver tissues (no=10) | 0 (0) | 0 (0) | 10 (100) | 10 (100) | 0 (0) | 0 (0) | 10 (100) | 10 (100) |
HepPar-1=hepatocyte paraffin antigen-1.